Search | Clinical Trials Finder

Conditions: Depressive Symptoms
Interventions: DepCare, Enhanced Usual Care; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Post-Traumatic Stress Disorder
Interventions: Carvedilol, Placebo; Drug
Lead sponsor: Columbia Northwest Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: San Diego, California • Lake Charles, Louisiana • Bellevue, Washington

Conditions: Domestic Violence, Depression, Quality of Life
Interventions: Active Comparator: the Community Health Worker -Personalized Support for Progress, Care as Usual- Social Worker; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Covid19, Critical Illness, High Intensity Interval Training, ICU, Intensive Care Units, Fitness Trackers
Interventions: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT), Comparator; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina • Nashville, Tennessee

Conditions: Depression
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Metastatic Breast Cancer
Interventions: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 20
States / cities: Duarte, California • La Jolla, California • Stanford, California + 15 more

Conditions: Erectile Dysfunction
Interventions: LEVITRA (vardenafil), placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 65
States / cities: Fairhope, Alabama • Homewood, Alabama • Huntsville, Alabama + 61 more

Conditions: Caregiver Stress Syndrome, Anxiety
Interventions: Mindfulness Coach, Active Comparator; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 21 Years and older
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Livingston, New Jersey • Monroe, New Jersey • New Brunswick, New Jersey

Conditions: Nicotine Dependence
Interventions: Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing; Device · Drug · Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV, Depression in Adults, Insulin Resistance, Cognitive Behavior Therapy
Interventions: Internet cognitive behavioral therapy (iCBT-D), Active Control (AC); Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Tobacco Use, Smoking, Smoking Cessation
Interventions: Cognitive-Motivational Feedback, Staff Tobacco Quit Line Referral Implementation Support, Consumer Incentives for Immediate Referral to a Tobacco Quit Line; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Idiopathic Inflammatory Myopathies
Interventions: Rapcabtagene autoleucel, Active Comparator Option; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 10
States / cities: Birmingham, Alabama • Zephyrhills, Florida • Augusta, Georgia + 7 more

Conditions: ANCA Associated Vasculitis (AAV)
Interventions: Rapcabtagene autoleucel, Active Comparator, Glucocorticoids; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 14
States / cities: Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 10 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: LNP023, Eculizumab, Ravulizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Orange, California • Augusta, Georgia + 2 more

Conditions: Families Experiencing Homelessness and/or Housing Instability, Housing Stability
Interventions: Guaranteed Income, Public Benefits Information Session; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: San Jose, California

Conditions: Holmium Laser Prostate Surgery, Radical Prostatectomy
Interventions: EMSELLA®, Sham Comparator Device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 2,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Hypertension, Preeclampsia
Interventions: Norethindrone 0.35 MG, Drospirenone; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Back Pain Lower Back Chronic, Chronic Pain
Interventions: Buprenorphine Buccal Film [Belbuca], Urine Drug Screening, actigraph, PROMIS 29, sit to stand test, numerical rating scale pain score, patient global impression of function, PROMIS - sleep; Drug · Other · Device + 1 more
Lead sponsor: Carolinas Pain Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy; Drug · Procedure · Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 66 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more

Conditions: Alcohol Abuse
Interventions: Brief Negotiated Interview, General Health Information; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 65 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Post Traumatic Stress Disorder (PTSD), Addiction, Alcohol Abuse
Interventions: N-Acetylcysteine (NAC) Treatment, Cognitive Behavioral Therapy (CBT), Inactive Placebo Oral Capsule, Functional magnetic resonance imaging (fMRI), Proton magnetic resonance spectroscopy (MRS) Imaging; Drug · Behavioral · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Obesity
Interventions: JITAI Enhanced Education Intervention Option, JITAI Self-Efficacy Intervention Option, JITAI Motivation Intervention Option, JITAI Self-Regulation Intervention Option, JITAI Generic Risk Alert Intervention Option (Active Comparator), Online Behavioral Obesity Treatment, JITAI No Treatment Intervention Option; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Toxicant Induced Chronic Multisymptom Illness and Associated Symptoms and Comorbidities
Interventions: Ubiquinone 100 mg Oral Soft Gel, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Insomnia
Interventions: Telemedicine CBT-I, Conventional office-based CBT-I; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Implementation Science Approach to Enhancing Depression Treatment in Collaborative Depression Care Settings ( DepCare )

Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

Realizing Opportunities for Self-Supported Improvement (ROSSI)

REmotely Monitored, Mobile Health-Supported High Intensity Interval Training After COVID-19 Critical Illness (REMM-HIIT-COVID-19)

Advancing Personalized Antidepressant Treatment Using PET/MRI

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia

mHealth Mindfulness With Patients With Serious Illness and Their Caregivers

Nicotine Withdrawal Symptoms and Smoking Relapse

The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV

Salvation Army Tobacco Quit Line Referral Implementation Trial

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Silicon Valley Guaranteed Income Project

HIFEM Technology for Post-Radical Prostatectomy and Post-Holmium Laser Prostate Surgery

A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Study of an Emergency Department-based Intervention to Reduce Alcohol Misuse in Older Adults

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

Miro-randomized Trial for Optimizing a JITAI to Reduce Dietary Lapses in Obesity Treatment

Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection

Non-inferiority Study of Telemedicine Versus Conventional CBT-I in Recently Hospitalized Patients With Insomnia